Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

C. Hawkes, “Olfaction in Neurodegenerative Disorder,” Advances in Oto-Rhino-Laryngology, Vol. 63, 2006, pp. 133-151. doi:10.1159/000093759

has been cited by the following article:

  • TITLE: Modification of the Brief Smell Identification Test by Introduction of a Placebo

    AUTHORS: Grete Kjelvik, Ole Bosnes, Ragnhild Omli, Liv Heidi Skotnes, Asta K. Håberg, Linda R. White

    KEYWORDS: B-SIT; Odor Identification; Scratch and Sniff Tests; Norwegian Population; Olfactory Testing; Neurodegenerative Diseases

    JOURNAL NAME: Neuroscience and Medicine, Vol.3 No.2, June 8, 2012

    ABSTRACT: Objective: To introduce the concept that there might be “nothing to smell” to the Brief Smell Identification Test (B-SIT), with a view to masking olfactory deficits, particularly from healthy control participants in research studies. Methods: Seventy-one elderly individuals, healthy for their age, were recruited to the study. They were blindfolded and carried out a modified B-SIT where one item had been replaced with a placebo, and one odour alternative answer to three other items was replaced by the alternative “none/other” (actual odour unchanged). Results: There was no overall difference in the median or mean score achieved by the cohort compared to results obtained previously using the conventional B-SIT. The replacement of the item “turpentine” with a placebo resulted in an improved score for the item in a Norwegian setting. The overall scores were not improved. Conclusions: It is possible to introduce the concept that there may be “nothing to smell” to the B-SIT without compromising the test for healthy control individuals. This may be a more appropriate approach to olfactory testing of control individuals or patients with suspected early neurodegenerative diseases.